Loading…
← CockpitCompetitor Analysis › ASPE Aspen Neuroscience, Inc.Open in the cockpit ↗

Aspen Neuroscience, Inc.ASPECompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Mkt cap
$349M
US dollars, full cap
$/day
$4.93M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-195.4 pp
WACC 8.9%
Hurdle
n/a
no reverse DCF
Close · USD$12.01
1D+0.1%
1W-13.1%
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a

What Aspen Neuroscience does

Employees: 117

Aspen Neuroscience at a glance

Size Aspen Neuroscience (ASPE) is a United States Health Care company (Biotechnology) with a market value of $349M, the 2957th largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.01 on 18 Nov 2026.

Capital Return on invested capital runs 195.4 points below its cost of capital (8.9% WACC).

Aspen Neuroscience financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$4.20M-$3.70M
EBITDAn/a-$55.1M-$49.8M
Net incomen/a-$62.1M-$48.6M
Free cash flown/a-$62.5M-$46.8M
Capital expendituren/a$9.69M$2.58M
Total debt$349M$350M$237M

Quarterly statements and history in the cockpit →

Aspen Neuroscience competitors and peer comparison

How Aspen Neuroscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aspen Neuroscience against its 20 peers (data as of 18 Nov 2026)
MeasureASPEPeer medianRank in peer set
ROIC minus cost of capital-195.4 pp-9.2 pplowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a

Questions

Which companies are Aspen Neuroscience's closest peers?
The cockpit's peer set: Medy-Tox (086900.KS), Lyell Immunopharma (LYEL), CorMedix (CRMD), GI Innovation (358570.KS), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Onconic Therapeutics (476060.KS), Medtide (3880.HK).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.